title: Clinical effects of ventricular assist system in end-stage cardiac failure. Advantages of left ventricular blood drainage for recovery from cardiac dysfunction.
abstract: OBJECTIVE
  Heart transplantation is extremely limited currently in Japan. As a consequence ventricular assist system implantation is employed the patient falls into end-stage cardiogenic shock. This preliminary report describes our initial clinical experience with use of 2 kinds of ventricular assist system for 13 Japanese patients.
  
  
  METHODS
  7 patients were supported by a left ventricular assist system with blood drainage from the left atrium (LA drainage Group) using a Toyobo ventricular assist system, while another 6 patients were supported by a left ventricular assist system with blood drainage from the left ventricle (LV drainage Group) using the Toyobo ventricular assist system (1 patient) or TCI-LVAS (5 patients).
  
  
  RESULTS
  The average duration of ventricular assist system support in the LV drainage Group was 112 days including two on-going patients (now at 39 days and 241 days) and in the LA drainage Group was 49 days. The average left ventricular ejection fraction at 3 weeks after ventricular assist system implantation was improved from 12.3 to 54% using the TCI-LVAS and from 14 to 33% using the Toyobo ventricular assist system with drainage from the left ventricle. However, this was decreased from 20 to 10% using the Toyobo ventricular assist system with drainage from the left atrium. The ventricular assist system was explanted in 4 patients (31%) with recovery of cardiac dysfunction and 3 were long survivors. The 2 on-going patients are awaiting heart transplantation. Thus the current survival rate overall is 38%. The survival rate (67%) is excellent in the LV drainage Group including 2 long survivors after explantation.
  
  
  CONCLUSIONS
  Ventricular assist system support with drainage from the left ventricle seems to be more advantageous for cardiac functional recovery than from the left atrium for end-stage heart failure.
authors.affiliation: Department of Surgery, Saitama Medical School, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kyo
authors.forename: H
authors.initials: H
authors.lastname: Tanabe
authors.forename: H
authors.initials: H
authors.lastname: Asano
authors.forename: H
authors.initials: H
authors.lastname: Ohuchi
authors.forename: H
authors.initials: H
authors.lastname: Nogaki
authors.forename: M
authors.initials: M
authors.lastname: Ishikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Yokote
authors.forename: T
authors.initials: T
authors.lastname: Koyanagi
authors.forename: H
authors.initials: H
authors.lastname: Noda
authors.forename: R
authors.initials: R
authors.lastname: Omoto
mesh_terms: D000328:Adult; D006353:Heart-Assist Devices; D006801:Humans; D008297:Male; D012770:Shock, Cardiogenic / Q000401:mortality / Q000628:therapy*; D018487:Ventricular Dysfunction, Left / Q000628:therapy*; D016277:Ventricular Function, Left / Q000502:physiology